Menu
Back to User profile » Dr Robert Smyth-Medina
Papers published by Dr Robert Smyth-Medina:
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI
Clinical Ophthalmology 2022, 16:4145-4151
Published Date: 13 December 2022
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:4035-4048
Published Date: 8 October 2021
Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:2743-2751
Published Date: 25 June 2021
Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial
Pepose JS, Hartman PJ, DuBiner HB, Abrams MA, Smyth-Medina RJ, Moroi SE, Meyer AR, Sooch MP, Jaber RM, Charizanis K, Klapman SA, Amin AT, Yousif JE, Lazar ES, Karpecki PM, Slonim CB, McDonald MB
Clinical Ophthalmology 2021, 15:79-91
Published Date: 8 January 2021
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2019, 13:215-216
Published Date: 24 January 2019
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:2637-2638
Published Date: 14 December 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:1921-1929
Published Date: 2 October 2018
An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations
Walters TR, Smyth-Medina RJ, Cockrum PC
Clinical Ophthalmology 2018, 12:943-947
Published Date: 21 May 2018